CON Stock Forecast & Price Target

Concentra Group Holdings is favored because its occupational health model benefits from employer and workers’ compensation reimbursement, leaving it largely insulated from Medicare, Medicaid, and managed-care risk while still capturing favorable state-regulated rate dynamics. Strong 3Q26 results showed adjusted EBITDA of $140.2 million on $622.1 million of revenue, with 22.5% margins, 2026 guidance raised to $2.36 billion to $2.38 billion of revenue and $505 million to $510 million of EBITDA, and free cash flow guidance reaffirmed at $220 million to $240 million. The outlook is further supported by broad-based visit and rate growth, 27.9% organic growth in onsite clinics, net leverage just under 3.0x, and an expanded $250 million buyback authorization, giving it room to fund growth, M&A, and shareholder returns.

Concentra Group Holdings is vulnerable to a downside case where expansion into high-reimbursement markets fails to offset weaker demand and topline pressure from an economic slowdown. In that scenario, adjusted EBITDA in 2027 would trail estimates by about 5%, signaling that earnings power could soften meaningfully if operating conditions deteriorate. The valuation would also compress to around 9.5x EBITDA, near recent trough levels of Concentra’s SEM parent, which suggests limited investor confidence in durable fundamentals.